V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ebola

Conditions

Ebola

Trial Timeline

Aug 1, 2017 → Mar 3, 2023

About V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine

V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine is a phase 2 stage product being developed by Merck for Ebola. The current trial status is completed. This product is registered under clinical trial identifier NCT03031912. Target conditions include Ebola.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03031912Phase 2Completed

Competing Products

20 competing products in Ebola

See all competitors